Apimeds Pharmaceuticals US (APUS) Depreciation & Amortization (CF) (2025)
Apimeds Pharmaceuticals US (APUS) reported Depreciation & Amortization (CF) of $3985.0 for Q4 2025, up 167.63% quarter-over-quarter from $1489.0 in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Depreciation & Amortization (CF) (2025) Analysis & Trends
Apimeds Pharmaceuticals US has reported Depreciation & Amortization (CF) for 1 years, with the latest figure at $3985.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization (CF) changed N/A year-over-year to $3985.0; the trailing twelve-month figure through Dec 2025 stood at $5474.0 (changed N/A YoY), and the FY2025 full-year result was $5706.0, changed N/A from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $3985.0, up from $1489.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $3985.0 in Q4 2025, with the low at $1489.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Apimeds Pharmaceuticals US | 13.93 Mn | 10.29 Mn | - | 3,985.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,985.00 |
| Dec 31, 2025 | 3,985.00 |
| Sep 30, 2025 | 1,489.00 |
| Sep 30, 2025 | 1,489.00 |